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Accepted 25 September 2015β-Glucans have beneficial health effects due to their immune modulatory properties. Oral
administration of β-glucans affects tumour growth, microbial infection, sepsis, and wound
healing. We hypothesized that pre-treatment with orally delivered soluble and particulate
β-glucans could ameliorate the development of aggravate dextran sulfate sodium (DSS)
induced intestinal inflammation. To study this,micewere orally pre-treatedwith β-glucans for
14 days. We tested curdlan (a particulate β-(1,3)-glucan), glucan phosphate (a soluble β-(1,3)-
glucan), and zymosan (a particle made from Saccharomyces cerevisiae, which contains around
55% β-glucans). Weight loss, colon weight, and feces score did not differ between β-glucan and
vehicle treated groups. However, histology scores indicated that β-glucan–treated mice had
increased inflammation at a microscopic level suggesting that β-glucan treatment worsened
intestinal inflammation. Furthermore, curdlan and zymosan treatment led to increased colonic
levels of inflammatory cytokines and chemokines, compared to vehicle. Glucan phosphate
treatment did not significantly affect cytokine and chemokine levels. These data suggest that
particulate and soluble β-glucansdifferentially affect the intestinal immune responses. However,
no significantdifferences inother clinical colitis scores between soluble andparticulate β-glucans
were found in this study. In summary, β-glucans aggravate the course of dextran sulfate sodium
(DSS)-induced intestinal inflammation at the level of the mucosa.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the






β-Glucans are glucose polymers consisting of a linear molecule
with (1-3)-β-D-glycosidic linkages with or without side chainor Liver and Intestinal R
68060.
.E.M. Heinsbroek).
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).branches bound by (1-6)-β-D-glycoside [1]. They are major
structural components of fungal cell walls and are also found in
plants and some bacteria. Immune stimulation and antitumoral
activities have been ascribed to β-glucans thought to be onlyesearch, Academic Medical Centre, Meibergdreef 69–71, 1105BK
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health effect of orally administered β-glucans was an antitumor
effect [3] which has been studied and confirmed extensively,
also in human studies [4]. In addition, oral administration of
fungal β-glucans has been described to give various other health
benefits during microbial infection [5,6], sepsis [7,8], radiation
injury [9,10], and wound healing [11].
Unlike other glucose polymers, β-glucans are not digested
upon oral administration but are taken up as they are in the
small intestine. Both particulate and soluble β-glucans are
absorbed by the gastrointestinal tract after which they can be
found in the serum and are able to affect the immune system
[5,12]. Oral administration of β-glucans has been shown to
increase the number of intraepithelial lymphocytes in the
intestine [13], increase TLR2 levels in the gut-associated
lymphoid tissue [5], and enhance phagocytic capacity of
peritoneal macrophages [12].
Dectin-1 is the main receptor for β-glucans on macrophages,
dendritic cells, and neutrophils and plays an important role in
anti-fungal immunity [14]. Upon β-glucan recognition dectin-1
induces various immune responses including phagocytosis, the
respiratory burst, production of numerous cytokines and
chemokines, and production of arachidonic acid metabolites
[14]. However, recently it was shown that dectin-1 is not involved
in the β-glucan–mediated protection against bacterial infection
[15], and other mechanisms like the involvement of the
complement system and immune system reprogramming are
also thought to play a role in the immunemodulatory effects of β-
glucans [16,17]. Research on dectin-1–deficient mice has shown
contradictory results in aggravate dextran sulfate sodium (DSS)-
induced colitis models, most likely due to a difference in the
microbiome composition between studies [18,19]. Hence, the role
of β-glucans in mucosal immune responses is unclear.
We investigated how pre-treatment with orally delivered
soluble and particulate β-glucans affects the development of
DSS-induced intestinal inflammation. DSS-induced intestinal
inflammation is themost widely usedmousemodel for human
inflammatory bowel diseases (IBD). DSS causes damage to the
epithelial lining of the intestine, increasing interactions of the
microbiota with the intestinal immune system, which leads
to an acute inflammation mainly involving innate immune
cells [20]. We used curdlan, glucan phosphate, and zymosan
to pre-treat mice before DSS-induced inflammation. Curdlan
from the Gram-negative bacterium Alcaligenes faecalis is a
particulate, tasteless, odorless and colorless substance that
consists of solely β-(1-3)–linked glucan [21]. Glucan phosphate
is isolated from Saccharomyces cerevisiae; like curdlan, it is
tasteless, odorless, and colorless and only contains β-(1-3)
glucose linkages. In contrast to curdlan, glucan phosphate is a
water soluble β-glucan [22]. Zymosan is a particle made from
Saccharomyces cerevisiae and is often used as a fungal model. It
consists of around 55% glucan, both β-(1-3)– and β-(1-6)–linked
glucan, 19% mannan, 15% protein, and small amounts of fat
and inorganic material [23].
We hypothesized that due to their immune modulatory
role these β-glucans may positively affect the course of
intestinal inflammation. The objective was to investigate
the effect of oral pre-treatment, with 3 different β-glucans or
β-glucan-containing preparations, in a mouse colitis model. A
widely used mouse DSS colitis model, which induces aninnate driven response, was used. In this study we show that
pre-treatment with β-glucans is not protective and worsens
intestinal inflammation in a model of DSS-induced colitis.
Hence, β-glucans may contribute to the pathogenesis of
innate driven acute colitis rather than improve the condition.2. Methods and materials
2.1. Mice
C57BL/6 mice were housed and maintained under specific
pathogen-free conditions in our animal facility at the Academic
Medical Centre in Amsterdam. The total sample size of mice
was 30, divided into 3 test groups of 8 for each group and
1 control group of 6. Animals were kept and handled in
accordance with the guidelines of the Animal Research Ethics
Committee of the University of Amsterdam.
2.2. Colitis experiments
Mice were sex-matched male or female and between 8 and
12 weeks of age at the time of study. Mice were pre-treated
with 1 mg/0.2 mL curdlan (Sigma), glucan phosphate, or
zymosan (Sigma) by oral gavage daily for 14 days before
inducing DSS colitis. This dose has previously been shown to
induce immune-modulating effects in mice [5]. Subsequently,
1.5% (w/v) DSS (TdB Consultancy, Uppsala, Sweden) was
added to the drinking water for 6 days. Fresh DSS solutions
were prepared daily. Body weights were recorded daily. After
6 days the mice were euthanized with CO2, and organs were
collected. Wet weights of the spleen and colon were recorded
together with the total length of the colon. Colon weight per
6 cm was used as a disease parameter. Feces were scored
as follows: (0) normal feces, (1) soft pellets, (2) thin feces,
(3) watery diarrhea, and (4) bloody diarrhea [18,24].
2.3. Histology
The longitudinally divided colons were rolled, fixed in 4%
formalin for 24 hours, and embedded in paraffin for routine
histology [18,24]. Anexperiencedpathologist evaluated formalin-
fixed hematoxylin and eosin–stained tissue sections micro-
scopically, in ablinded fashion. Colonswere graded from0 to 4as
an indication of incidence and severity of inflammatory lesions
based on the extent of the area involved, the number of follicle
aggregates, edema, fibrosis, hyperplasia, erosion/ulceration,
crypt loss, and infiltration of granulocytes and mononuclear
cells as indicated in the Table. The total inflammation score was
calculated as the average score of the above [18,24].
2.4. Measurements of colonic cytokines
Frozen colonic tissue was homogenized in Greenberger Lysis
Buffer (150mmol/L NaCl, 15mmol/L Tris, 1mmol/L MgCl · 6H2O,
1mmol/L CaCl2, 1% Triton) with protease inhibitor cocktail from
Roche (11697498001), pH7.4, diluted 1:1withphosphate-buffered
saline, for 30 minutes on ice using a tissue homogeniser [18,25].
Protein concentrations of interleukin (IL)–12, interferon-γ
(IFN-γ), tumor necrosis factor α (TNF-α), IL-10, chemokine
Table – Colitis total inflammation score
score 0 1 2 3 4
Area involved 0% 1%-10% 10%-25% 25%-50% >50%
Follicles Normal (0-1) Minimal (2-3) Mild (4-5) Moderate (6-7) Severe (>7)
Edema Absent Minimal Mild Moderate Severe
Fibrosis Absent Minimal Mild Moderate Severe
Erosion/ulceration 0% 1%-10% 10%-25% 25%-50% >50%
Crypt loss 0% 1%-10% 10%-25% 25%-50% >50%
Granulocytes Normal Minimal increase Mild increase Moderate increase Severe increase
Mononuclear cells Normal Minimal increase Mild increase Moderate increase Severe increase
The total inflammation score was determined by the average score of the following criteria: area involved, the number of follicle aggregates,
edema, fibrosis, hyperplasia, erosion/ulceration, crypt loss and infiltration of granulocytes and mononuclear cells.
Fig. 1 – β-Glucan pre-treatment in DSS-induced intestinal inflammation. A,Micewere given vehicle (n = 6), glucan phosphate (n = 8),
curdlan (n = 8) or zymosan (n = 8) once daily by oral gavage for twoweeks before inducing DSS colitiswith 1.5% (w/v) DSS in drinking
water. Themice were euthanized after 6 days of DSS treatment. B, Body weights were measured as indication of disease severity
in this model; weights are shown as percentage of weight compared to those on day 1. C, Colons were weighed as a measure of
inflammation, shown as weight per 6 cm colon. D, Colon pathology scores were determined by an experienced pathologist. Colons
were graded from 0 to 4 points as indicated in Table. E, Fecal scores were given ranging from 0 to 4 points. The values represent the
means ± SE. One-way ANOVAwith bonferonni post-test was used for statistical analysis. *P < .05.
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cytometric bead array multiplex assay (BD Biosciences, San
Jose, CA, USA) according to manufacturer protocol using flow
cytometry (BD LSRFortessa). In some colon lysates too little
protein was detected whichmade the samples unsuitable for
cytokine determination; accordingly the number of samples
was reduced in some groups.
2.5. Statistical analyses
The total sample size (n = 30), divided over 3 test groups (n = 8
for each group) and one control group (n = 6), was determined
according to a prior statistical power analysis based onprevious
studies using Query Advisor, using a relevant difference in
colonweight of 45mgwith a standard deviation of 10mg in the
last 6 cm of the colon with α = .05 and power = .80 [18,24,25]. All
data are expressed asmeans ± SE. The statistical significance of
the differences was evaluated using one-way analysis of
variance (ANOVA) with Bonferonni posttest. Statistical signifi-
cance was defined as P < .05.3. Results
To determine if β-glucan feeding can reduce intestinal inflamma-
tion in DSS-induced colitis, we tested 2 different pure β-Fig. 2 – Colon histology of β-glucan pre-treatment in DSS-induced
sections stained with hematoxylin and eosin. In inflamed areas c
of cell infiltration in the mucosa. Cell infiltration frequently exte
muscularis externa (arrowheads). Bar, 200 μm.glucans and a β-glucan–containing particle, zymosan. Curdlan
and glucan phosphate both consist solely of β-(1-3) glucose
linkages; glucan phosphate is soluble, and curdlan is particu-
late. Mice were pre-treated with β-glucans by oral gavage for 14
days before inducing intestinal inflammation with DSS for 6
days (Fig. 1A). β-Glucan pre-treatment had no effect on
bodyweights (data not shown). After DSS-induced colitis we
found that all groups lost weight, and there was no significant
difference in weight loss among the groups (Fig. 1B) nor a
significant difference in colon weight (Fig. 1C). Colonic inflam-
mation was scored by an experienced pathologist according to
the Table and demonstrated that all 3 β-glucan–treated groups
had a significant increase in colon pathology compared to the
vehicle treated group (Figs. 1D and 2). The majority of mice had
bloody diarrhea, and no significant differences in fecal score
were found (Fig. 1E).
Next we investigated colonic levels of IL-12, IFN-γ, TNF-α,
IL-10, CCL-2, and IL-6 in colon tissue. Levels of IFN-γ and IL-12
were below detection, as to be expected in this model [20].
TNF-α (Fig. 3A) and CCL-2 (Fig. 3B) were significantly
increased in curdlan-treated mice compared to vehicle. IL-6
levels were also increased although not significantly (Fig. 3D).
Zymosan-treated mice had significantly higher levels of CCL-2
and displayed a trend towards increased IL-6 compared to
vehicle-treated mice (Fig. 3B and D). Unlike curdlan and
zymosan, glucan phosphate–treated mice did not showintestinal inflammation. Representative picture of the colon
rypt loss occurred (asterisk), accompanied by a large amount
nded to the submucosa (arrows) and occasionally to the
Fig. 3 – Inflammatory cytokines levels in colon.Micewere given vehicle, glucan phosphate, curdlan or zymosan oncedaily for two
weeks before inducing DSS colitis with 1.5% (w/v) DSS in drinking water. Cytokine protein concentrations were determined in
colon lysates, vehicle (n = 4), glucan phosphate (n = 6), curdlan (n = 5) or zymosan (n = 8). A, TNF-α concentrations. B, CCL-2
concentrations. C, IL-10 concentrations. D, IL-6 concentrations. The sample means are indicated with a line. One-way ANOVA
with bonferonni post-test was used for statistical analysis. *P < .05.
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measured cytokines. Interestingly, glucan phosphate–treated
mice were the only group with increased IL-10 levels (Fig. 3C).
Together our data show that β-glucan feeding exacerbates
intestinal inflammation in this DSS-induced colitis model.4. Discussion
The cause of human IBD is still unclear, and current drug
treatments have severe side effects and are frequently unsuc-
cessful. Therefore, new insights on the pathogenesis of IBD and
new treatment options are still required. While various health
benefits are reported, the effect of β-glucans on intestinal
inflammation is still uncertain. We hypothesized that due
to their immune modulatory role β-glucans positively affect
the course of intestinal inflammation. Therefore, we tested
three β-glucan preparations that differed in origin, composition,
structure, purity, and solubility. Our results however show no
difference in clinical scores of DSS colitis between the β-glucan
and vehicle treated groups. Interestingly, the histology score
indicated that β-glucan–treated mice had increased inflamma-
tion, suggesting that β-glucan treatment worsens intestinalinflammation. Together our results suggest that both soluble
and particulate β-glucans aggravate the course of DSS-induced
inflammation, which refutes our hypothesis.
In our experiments we induced DSS-mediated intestinal
inflammation, which is the most widely usedmouse model for
human colitis. In this model acute inflammation is induced by
DSS, which decreases the mucus layer and disrupts the
epithelial barrier [26]. Although regularly considered an acute
injury rather than an IBD model, this model does demonstrate
clinical and histopathological features reflecting those seen in
human IBD [20]. Furthermore, a study byMelgar et al [27] shows
that a variety of therapeutic agents for IBD ameliorated the
inflammatory response in DSS-induced colitis with similar
results to the ones reported in IBDpatients. In contrast, te Velde
et al [28] showed that during DSS colitis, 15 of 32 genes are
transcriptionally regulated in a similar manner as in human
IBD, showing the limitations of this model. Together, this
indicates that DSS-induced colitis in C57BL/6mice is relevant to
human IBD pathogenesis and treatment.
Curdlanandzymosanareknown to inducepro-inflammatory
cytokine production by macrophages via dectin-1 signaling
[29,30]. In our study, treatment with curdlan resulted in the
highest inflammation score and the highest levels of colonic
1111N U T R I T I O N R E S E A R C H 3 5 ( 2 0 1 5 ) 1 1 0 6 – 1 1 1 2pro-inflammatory cytokines compared to our other groups,
suggesting this β-glucan is the most potent in augmenting
mucosal inflammation. Zymosan and glucan phosphate
treatment gave only a slightly lower inflammation score
compared to curdlan, but of these two only zymosan treated
mice had increased levels of CCL-2. Particulate β-glucans are
known to trigger dectin-1 signaling while soluble glucan
phosphate is a dectin-1 antagonist [29,30]. However, glucan
phosphate also has agonist properties as shown by its ability
to activate intracellular signaling pathways, increase resis-
tance to infection, and enhance wound repair [31–33]. The
effect on the immune system may depend on the source
of β-glucan since a recent study suggests that bacterial
β-glucans, of which curdlan is one member, can prevent DSS
colitis [34].
Our hypothesis was based on the beneficial effects seen
with β-glucan treatment during microbial infection and
wound healing [5,6,8,11]. In contrast, our results suggest
that β-glucans aggravate intestinal inflammation in the
present model. Further studies with additional mouse
strains and disease models are required to establish the
generality of our observation. The increased inflammation
found upon β-glucan treatment may be due to recently
described training of the immune system: β-glucan
treatment has been shown to enhance cytokine production
upon subsequent infection, shown to be a dectin-1–mediated
process [17]. Furthermore, oral glucan administration increased
pattern recognition receptor expression in the gut associated
lymphoid tissue of mice, and protected against subsequent
infections [5]. Such a primed immune response may be useful
in the fight against specific infections but detrimental
during intestinal inflammation upon challenge by intestinal
microbiota, inwhich case, amore tolerant immune systemmay
be advantageous.
In conclusion, due to their earlier described beneficial
effect during wound healing and infection we hypothesized
that β-glucans could reduce intestinal inflammation. How-
ever, we found that curdlan, zymosan and glucan phos-
phate aggravated DSS-induced colitis, suggesting a more
detrimental role for intestinal inflammation rather than a
beneficial one.Conflict of interest
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